title: Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation.
abstract: To assess whether asymmetric stent expansion affects suppression of neointimal hyperplasia after sirolimus-eluting stent implantation, 64 patients in the SIRolImUS-coated Bx Velocity stent trial who underwent single 18-mm stent implantation and 3-dimensional intravascular ultrasonography at 8-month follow-up were enrolled. To assess the longitudinal stent asymmetric expansion, 2 cross sections with a maximal/minimal stent area were chosen in each patient. To assess for tomographic stent asymmetric expansion, stent eccentricity was determined by dividing the minimum stent diameter by the maximum stent diameter. At the 2 cross sections with a maximal/minimal stent area, a sirolimus-eluting stent reduced neointimal hyperplasia significantly with no interaction between the treatment and stent areas. A sirolimus-eluting stent also significantly reduced neointimal hyperplasia in the concentric and eccentric stent groups.
authors.affiliation: Center for Research in Cardiovascular Interventions, Stanford University, Stanford, CA, USA.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneda
authors.forename: Junya
authors.initials: J
authors.lastname: Ako
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Terashima
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Morino
authors.forename: Paul G
authors.initials: PG
authors.lastname: Yock
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Moses
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fitzgerald
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000000981:diagnostic imaging; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000628:therapy; D011446:Prospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology* / Q000601:surgery; D018084:Ultrasonography, Interventional
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus